Greetings from Day 1 at ECTRIMS in Berlin! Today, we're talking about pharmaceutical company Novartis seeking approval from the U.S. Food & Drug Administration and the European Medicines Agency for siponimod, a once-daily oral medication that significantly reduces disability progression for people living with secondary progressive MS.
LINKSIf your podcast app doesn’t show these links, you’ll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com
Download the RealTalk MS App for iOS
Download the RealTalk MS App for Android
Novartis files for FDA & EMA Approval of Siponimod
Give RealTalk MS a Rating & Review
Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 57 Hosted By: Jon Strum Guest: Professor Reinhard Hohfeld
Tags: MS, MultipleSclerosis, ECTRIMS2018, Siponimod, RealTalkMS